Gasotransmitters is a class of neurotransmitters. The molecules are distinguished from other bioactive endogenous gaseous signaling molecules based on a need to meet distinct characterization criteria. Currently, only nitric oxide, carbon monoxide, and hydrogen sulfide are accepted as gasotransmitters. According to in vitro models, gasotransmitters, like other gaseous signaling molecules, may bind to gasoreceptors and trigger signaling in the cells.
The name gasotransmitter is not intended to suggest a gaseous physical state such as Infintesimal small gas bubbles; the physical state is dissolution in complex and cytosol.
The three gases have similar features and, in theory, participate in shared signaling pathways, although their actions can either be synergistic or antagonistic. Nitric oxide and hydrogen sulfide are highly reactive with numerous molecular targets, whereas carbon monoxide is relatively stable and metabolically inert predominately limited to interacting with ferrous ion complexes within mammalian organisms. The scope of biological functions are different across biological systems.
Gasotransmitters are under investigation in disciplines such as: biosensing, immunology, neuroscience, gastroenterology, and many other fields to include pharmaceutical development initiatives. While biomedical research has received the most attention, gasotransmitters are under investigation throughout biological systems. Many analytical tools have been developed to study gasotransmitters in vitro.
Relative to carbon monoxide and hydrogen sulfide, NO is exceptional due to the fact it is a radical gas. NO is highly reactive (having a lifetime of a few seconds), yet diffuses freely across membranes. These attributes make NO ideal for a transient paracrine (between adjacent cells) and autocrine (within a single cell) signaling molecule.
It is a known bioproduct in almost all types of organisms, ranging from bacteria to plants, fungi, and animal cells.
The production of NO is elevated in populations living at high altitudes, which helps these people avoid hypoxia by aiding in pulmonary vasculature vasodilation. The endothelium (inner lining) of uses NO to signal the surrounding smooth muscle to relax, thus resulting in vasodilation and increasing blood flow. NO contributes to vessel homeostasis by inhibiting vascular smooth muscle contraction and growth, platelet aggregation, and leukocyte adhesion to the endothelium. Humans with atherosclerosis, diabetes, or hypertension often show impaired NO pathways. In the context of hypertension, the vasodilatory mechanism follows: NO acts through the stimulation of the soluble guanylate cyclase, which is a heterodimeric enzyme with subsequent formation of cyclic-GMP. Cyclic-GMP activates protein kinase G, which causes reuptake of Ca2+ and the opening of calcium-activated potassium channels. The fall in concentration of Ca2+ ensures that the myosin light-chain kinase (MLCK) can no longer phosphorylate the myosin molecule, thereby stopping the crossbridge cycle and leading to relaxation of the smooth muscle cell.
NO is also generated by phagocytes (, , and ) as part of the human immune response. Phagocytes are armed with inducible nitric oxide synthase (iNOS), which is activated by interferon-gamma (IFN-γ) as a single signal or by tumor necrosis factor (TNF) along with a second signal.
Two important biological reaction mechanisms of NO are S-nitrosation of thiols, and nitrosylation of transition metal ions. S-nitrosation involves the (reversible) conversion of thiol groups, including cysteine residues in proteins, to form S-nitrosothiols (RSNOs). S-Nitrosation is a mechanism for dynamic, post-translational regulation of most or all major classes of protein.
There are several mechanisms by which NO has been demonstrated to affect the biology of living cells. These include oxidation of iron-containing proteins such as ribonucleotide reductase and aconitase, activation of the soluble guanylate cyclase, ADP ribosylation of proteins, protein sulfhydryl group nitrosylation, and iron regulatory factor activation. NO has been demonstrated to activate NF-κB in peripheral blood mononuclear cells, an important transcription factor in iNOS gene expression in response to inflammation.
In mammals, CO is produced through many enzymatic and non-enzymatic pathways. The most extensively studied source is the catabolic action of heme oxygenase (HMOX) which has been estimated to account for 86% of endogenous CO production. Other contributing sources include: the microbiome, cytochrome P450 reductase, human acireductone dioxygenase, tyrosinase, lipid peroxidation, , and other oxidative mechanisms. Similarly, the velocity and catalytic activity of HMOX can be enhanced by a plethora of dietary substances and xenobiotics to increase CO production.
The biomedical study of CO traces back to factitious airs in the 1790s when Thomas Beddoes, James Watt, James Lind, and many others investigated beneficial effects of hydrocarbonate (water gas) inhalation. Following Solomon Snyder's first report that CO is a normal neurotransmitter in 1993, CO has received significant clinical attention as a biological regulator. Unlike NO and , CO is an inert molecule with remarkable chemical stability capable of diffusing through membranes to exert its effects locally and in distant tissues. CO has been shown to interact with molecular targets including soluble guanylyl cyclase, mitochondrial oxidases, catalase, nitric oxide synthase, mitogen-activated protein kinase, PPAR gamma, HIF1A, NRF2, , cystathionine beta synthase, and numerous other functionalities. It is widely accepted that CO primarily exerts its effects in mammals primarily through interacting with ferrous ion complexes such as the Prosthetic group heme moiety of . Aside from Fe2+ interactions, CO may also interact with zinc within metalloproteinases, non-metallic histidine residues of certain ion channels, and various other metallic targets such nickel and molybdenum.
acts as a relaxant of [[smooth muscle]] and as a [[vasodilator]]. Though both NO and have been shown to relax blood vessels, their mechanisms of action are different: while NO activates the enzyme [[guanylyl cyclase]], activates ATP-sensitive potassium channels in smooth muscle cells. Researchers are not clear how the vessel-relaxing responsibilities are shared between NO and . However, there exists some evidence to suggest that NO does most of the vessel-relaxing work in large vessels and is responsible for similar action in smaller blood vessels. deficiency can be detrimental to the vascular function after an acute myocardial infarction (AMI). therapy reduces myocardial injury and reperfusion complications. Due to its effects similar to NO (without its potential to form [[peroxides]] by interacting with [[superoxide]]), is now recognized as potentially protecting against cardiovascular disease.
Recent findings suggest strong cellular crosstalk of NO and , demonstrating that the vasodilatatory effects of these two gases are mutually dependent. Additionally, reacts with intracellular S-Nitrosothiol to form the smallest S-nitrosothiol (HSNO), and a role of in controlling the intracellular S-nitrosothiol pool has been suggested.
|
|